Novo Nordisk halted a planned extension of its Alzheimer’s semaglutide study after the Evoke and Evoke-plus pills failed to reduce cognitive decline by 20% compared to a placebo.Mike Doustdar implemented a 10% workforce reduction and management reshuffles following the disappointing results, which led to a drop of more than 12% in Novo Nordisk’s shares on the Copenhagen exchange.Maria Carrillo stated that while semaglutide missed expectations in Alzheimer’s treatment, ongoing research into different mechanisms of this drug class will continue.